TFDA holds expert meeting to discuss and review UBI's application to manufacture its COVID-19 vaccine UB-612


PublishTime:2021-08-16
The Taiwan Food and Drug Administration (TFDA) of the Ministry of Health and Welfare pointed out that it had invited domestic experts on August 15 to a meeting to discuss and review United BioPharma Inc's (UBI) application to manufacture its COVID-19 vaccine UB-612 (the UBI vaccine). Because the UBI vaccine fails to meet the two efficacy standards for granting the Emergency Use Authorization (EUA) to domestically-produced vaccines, after holding a vote on UBI's application at the meeting, experts recommended that the TFDA approval for the UBI's request for the manufacture of its COVID-19 vaccine not be granted.